ICU Medical price target raised to $172 from $153 at Piper Sandler

Piper Sandler raised the firm’s price target on ICU Medical (ICUI) to $172 from $153 and keeps an Overweight rating on the shares. The firm notes ICU reported Q3 results, including revenue upside across all segments, healthy margin outperformance, and a wide EPS beat. This contributed to management resetting EBITDA and EPS guidance meaningfully higher to account for the overage. Piper likes that the implied outlook for Q4 was prudently left unchanged.